Report cover image

Kidney Cancer Drugs Market Growth, Size, Trends Analysis - By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Mar 27, 2025
Length 261 Pages
SKU # SPER20042884

Description

Kidney Cancer Drugs Market Introduction and Overview

According to SPER market research, ‘Kidney Cancer Drugs Market Size- By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Kidney Cancer Drugs Market is predicted to reach 11.56 billion by 2034 with a CAGR of 5.83%.

Kidney cancer drugs are medications and therapies used to treat kidney cancer, also referred to as renal cell carcinoma (RCC) or renal cell adenocarcinoma. These medications are intended to target cancer cells, slow their growth, and/or boost the body’s immune response against cancer.

Restraints:The lack of appropriate regulatory standards for medicine prescriptions, as well as a preference for low-cost generic kidney cancer treatments, are anticipated to stymie the worldwide drug industry. Furthermore, medications that destroy cancer cells are toxic to healthy cells in the body. This produces many negative effects in patients, the most common of which are gastrointestinal problems, hair loss, tiredness, and skin illnesses. As a result, the negative aspects of kidney cancer medications are impeding market growth.

Scope of the Report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Cancer Type, By Therapy, By Drug Class, By Route of Administration, By Distribution Channel.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

Active Biotech AB, Amgen, Inc, Astellas Pharma Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eisai Co., Ltd, Exelixis, Inc, F. Hoffmann-La Roche Ltd, Genentech, Inc, GSK plc, Helsinn Healthcare SA, Johnson & Johnson Services, Inc, Merck & Co., Inc.

Kidney Cancer Drugs Market Segmentation:

By Cancer Type:

Based on the Cancer Type, Global Kidney Cancer Drugs Market is segmented as; Renal cell carcinoma, Transitional cell cancer, Wilms tumor, Renal sarcoma.

By Therapy:

Based on the Therapy, Global Kidney Cancer Drugs Market is segmented as; Targeted therapy, Immunotherapy, Chemotherapy, Other therapies.

By Drug Class:

Based on the Drug Class, Global Kidney Cancer Drugs Market is segmented as; Angiogenesis inhibitors, Monoclonal antibodies, mTOR inhibitors, Cytokine immunotherapy, Other drug classes.

By Route of Administration:

Based on the Route of Administration, Global Kidney Cancer Drugs Market is segmented as; Oral, Intravenous, Subcutaneous.

By Distribution Channel:

Based on the Distribution Channel, Global Kidney Cancer Drugs Market is segmented as; Hospital pharmacy, Brick and mortar, E-commerce.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

261 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Kidney Cancer Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Kidney Cancer Drugs Market
7. Global Kidney Cancer Drugs Market, By Cancer Type (USD Million) 2021-2034
7.1. Renal cell carcinoma (RCC)
7.2. Transitional cell cancer
7.3. Wilms tumor
7.4. Renal sarcoma
8. Global Kidney Cancer Drugs Market, By Therapy (USD Million) 2021-2034
8.1. Targeted therapy
8.2. Immunotherapy
8.3. Chemotherapy
8.4. Other therapies
9. Global Kidney Cancer Drugs Market, By Drug Class (USD Million) 2021-2034
9.1. Angiogenesis inhibitors
9.2. Monoclonal antibodies
9.3. mTOR inhibitors
9.4. Cytokine immunotherapy (IL-2)
9.5. Other drug classes
10. Global Kidney Cancer Drugs Market, By Route of Administration (USD Million) 2021-2034
10.1. Oral
10.2. Intravenous
10.3. Subcutaneous
11. Global Kidney Cancer Drugs Market, By Distribution Channel (USD Million) 2021-2034
11.1. Hospital pharmacy
11.2. Brick and mortar
11.3. E-commerce
12. Global Kidney Cancer Drugs Market, (USD Million) 2021-2034
12.1. Global Kidney Cancer Drugs Market Size and Market Share
13. Global Kidney Cancer Drugs Market, By Region, (USD Million) 2021-2034
13.1. Asia-Pacific
13.1.1. Australia
13.1.2. China
13.1.3. India
13.1.4. Japan
13.1.5. South Korea
13.1.6. Rest of Asia-Pacific
13.2. Europe
13.2.1. France
13.2.2. Germany
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.2.6. Rest of Europe
13.3. Middle East and Africa
13.3.1. Kingdom of Saudi Arabia
13.3.2. United Arab Emirates
13.3.3. Qatar
13.3.4. South Africa
13.3.5. Egypt
13.3.6. Morocco
13.3.7. Nigeria
13.3.8. Rest of Middle-East and Africa
13.4. North America
13.4.1. Canada
13.4.2. Mexico
13.4.3. United States
13.5. Latin America
13.5.1. Argentina
13.5.2. Brazil
13.5.3. Rest of Latin America
14. Company Profile
14.1. Active Biotech AB
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. Amgen, Inc
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Astellas Pharma Inc
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. AstraZeneca PLC
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Bayer AG
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Bristol-Myers Squibb Company
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Eisai Co., Ltd
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Exelixis, Inc
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. F. Hoffmann-La Roche Ltd
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Genentech, Inc
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. GSK plc
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments
14.12. Helsinn Healthcare SA
14.12.1. Company details
14.12.2. Financial outlook
14.12.3. Product summary
14.12.4. Recent developments
14.13. Johnson & Johnson Services, Inc
14.13.1. Company details
14.13.2. Financial outlook
14.13.3. Product summary
14.13.4. Recent developments
14.14. Merck & Co., Inc
14.14.1. Company details
14.14.2. Financial outlook
14.14.3. Product summary
14.14.4. Recent developments
14.15. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us